Vladimir Tolmachev - Search Results

Year	Number of Results
2002	5
2003	6
2004	9
2005	9
2006	8
2007	19
2008	7
2009	10
2010	17
2011	22
2012	15
2013	12
2014	17
2015	11
2016	17
2017	11
2018	19
2019	23
2020	19
2021	18
2022	15
2023	17
2024	4

1

Altai M, Membreno R, Cook B, Tolmachev V, Zeglis BM. Altai M, et al. Among authors: tolmachev v. J Nucl Med. 2017 Oct;58(10):1553-1559. doi: 10.2967/jnumed.117.189944. Epub 2017 Jul 7. J Nucl Med. 2017. PMID: 28687600 Free PMC article. Review.

2

Basic and practical concepts of radiopharmaceutical purification methods.

Molavipordanjani S, Tolmachev V, Hosseinimehr SJ. Molavipordanjani S, et al. Among authors: tolmachev v. Drug Discov Today. 2019 Jan;24(1):315-324. doi: 10.1016/j.drudis.2018.09.018. Epub 2018 Sep 29. Drug Discov Today. 2019. PMID: 30278224 Review.

3

Affibody Molecules as Targeting Vectors for PET Imaging.

Tolmachev V, Orlova A. Tolmachev V, et al. Cancers (Basel). 2020 Mar 11;12(3):651. doi: 10.3390/cancers12030651. Cancers (Basel). 2020. PMID: 32168760 Free PMC article. Review.

4

Radionuclides in Diagnostics and Therapy of Malignant Tumors: New Development.

Tolmachev V, Vorobyeva A. Tolmachev V, et al. Cancers (Basel). 2022 Jan 7;14(2):297. doi: 10.3390/cancers14020297. Cancers (Basel). 2022. PMID: 35053459 Free PMC article.

5

Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond.

Garousi J, Orlova A, Frejd FY, Tolmachev V. Garousi J, et al. Among authors: tolmachev v. EJNMMI Radiopharm Chem. 2020 Jun 23;5(1):16. doi: 10.1186/s41181-020-00094-w. EJNMMI Radiopharm Chem. 2020. PMID: 32577943 Free PMC article. Review.

6

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.

Yin W, Xu T, Ding H, Zhang J, Bodenko V, Tretyakova MS, Belousov MV, Liu Y, Oroujeni M, Orlova A, Tolmachev V, Gräslund T, Vorobyeva A. Yin W, et al. Among authors: tolmachev v. J Control Release. 2023 Mar;355:515-527. doi: 10.1016/j.jconrel.2023.02.005. Epub 2023 Feb 14. J Control Release. 2023. PMID: 36773960 Free article.

7

Phase I clinical evaluation of ^99mTc-labeled Affibody molecule for imaging HER2 expression in breast cancer.

Bragina O, Chernov V, Larkina M, Rybina A, Zelchan R, Garbukov E, Oroujeni M, Loftenius A, Orlova A, Sörensen J, Frejd FY, Tolmachev V. Bragina O, et al. Among authors: tolmachev v. Theranostics. 2023 Sep 4;13(14):4858-4871. doi: 10.7150/thno.86770. eCollection 2023. Theranostics. 2023. PMID: 37771776 Free PMC article. Clinical Trial.

8

Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology.

Krasniqi A, D'Huyvetter M, Devoogdt N, Frejd FY, Sörensen J, Orlova A, Keyaerts M, Tolmachev V. Krasniqi A, et al. Among authors: tolmachev v. J Nucl Med. 2018 Jun;59(6):885-891. doi: 10.2967/jnumed.117.199901. Epub 2018 Mar 15. J Nucl Med. 2018. PMID: 29545374 Free article. Review.

9

Radiolabeled probes targeting tyrosine-kinase receptors for personalized medicine.

Altai M, Orlova A, Tolmachev V. Altai M, et al. Among authors: tolmachev v. Curr Pharm Des. 2014;20(14):2275-92. doi: 10.2174/13816128113196660667. Curr Pharm Des. 2014. PMID: 24025099 Review.

10

The emerging role of radionuclide molecular imaging of HER2 expression in breast cancer.

Tolmachev V, Orlova A, Sörensen J. Tolmachev V, et al. Semin Cancer Biol. 2021 Jul;72:185-197. doi: 10.1016/j.semcancer.2020.10.005. Epub 2021 Jan 16. Semin Cancer Biol. 2021. PMID: 33465471 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

274 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Results by year